280 related articles for article (PubMed ID: 20671266)
1. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.
Park JT; Chen X; Tropè CG; Davidson B; Shih IeM; Wang TL
Am J Pathol; 2010 Sep; 177(3):1087-94. PubMed ID: 20671266
[TBL] [Abstract][Full Text] [Related]
2. Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells.
Gupta N; Xu Z; El-Sehemy A; Steed H; Fu Y
Gynecol Oncol; 2013 Jul; 130(1):200-6. PubMed ID: 23542683
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.
Jung SG; Kwon YD; Song JA; Back MJ; Lee SY; Lee C; Hwang YY; An HJ
Cancer Sci; 2010 Sep; 101(9):1977-83. PubMed ID: 20624166
[TBL] [Abstract][Full Text] [Related]
5. Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer.
Chen X; Stoeck A; Lee SJ; Shih IeM; Wang MM; Wang TL
Oncotarget; 2010 Jul; 1(3):210-8. PubMed ID: 20953350
[TBL] [Abstract][Full Text] [Related]
6. Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
Price JC; Azizi E; Naiche LA; Parvani JG; Shukla P; Kim S; Slack-Davis JK; Pe'er D; Kitajewski JK
PLoS One; 2020; 15(6):e0233962. PubMed ID: 32525899
[TBL] [Abstract][Full Text] [Related]
7. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
[TBL] [Abstract][Full Text] [Related]
8. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.
Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama S; Otsuki Y; Miyazaki K
Am J Clin Pathol; 2012 Oct; 138(4):535-44. PubMed ID: 23010708
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
[TBL] [Abstract][Full Text] [Related]
10. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
11. Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin.
Tzeng TJ; Cao L; Fu Y; Zeng H; Cheng WH
PLoS One; 2014; 9(7):e101664. PubMed ID: 25010594
[TBL] [Abstract][Full Text] [Related]
12. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
13. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
14. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
[TBL] [Abstract][Full Text] [Related]
15. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
Sherman-Samis M; Onallah H; Holth A; Reich R; Davidson B
Gynecol Oncol; 2019 Jun; 153(3):651-660. PubMed ID: 30904337
[TBL] [Abstract][Full Text] [Related]
16. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
17. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
[TBL] [Abstract][Full Text] [Related]
19. FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
Tassi RA; Gambino A; Ardighieri L; Bignotti E; Todeschini P; Romani C; Zanotti L; Bugatti M; Borella F; Katsaros D; Tognon G; Sartori E; Odicino F; Romualdi C; Ravaggi A
Br J Cancer; 2019 Oct; 121(7):584-592. PubMed ID: 31434988
[TBL] [Abstract][Full Text] [Related]
20. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
